This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision (EYE) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.
Masimo's (MASI) Rad-G with Temperature Receives CE Marking
by Zacks Equity Research
Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.
Abbott (ABT) Gets Canadian Nod for FreeStyle Libre Expanded Use
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.
Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF
by Zacks Equity Research
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business and Professional Service segments perform impressively in fiscal Q4.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter 2021 results benefit from strong segmental performance.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Zacks.com featured highlights include: Skyworks, ParkerHannifin, Toll Brothers, Abbott Lab and FedEx
by Zacks Equity Research
Zacks.com featured highlights include: Skyworks, ParkerHannifin, Toll Brothers, Abbott Lab and FedEx
Is Abbott (ABT) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.
DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.
PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.
Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines
by Zacks Equity Research
Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.
5 Dividend Growth Stocks Poised for Outperformance
by Sweta Killa
Dividend growth stocks like Skyworks Solutions (SWKS), ParkerHannifin (PH), Toll Brothers (TOL), Abbott Laboratories (ABT) and FedEx (FDX) seem poised to outperform.
February Ends in Green Amid Extreme Volatility: 5 Top Picks
by Nalak Das
We have narrowed down our search to five corporate behemoths that suffered a blow in last month's turmoil. These are AAPL, MSFT, FB, ABT and DHR.
Why Is Abbott (ABT) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
LHC Group (LHCG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health and hospice admissions.
Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.
NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.
Abbott (ABT) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $121.58, moving -0.65% from the previous trading session.
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.
Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.